Streetbeat News

Price Targets

LULU

Keybanc analyst Noah Zatzkin maintains an Overweight rating on Lululemon Athletica (NASDAQ:LULU) and raises the price target from $390 to $400.

Portfolio Pulse from richadhand@benzinga.com

June 02, 2023 | 9:04 am

EPR

Keybanc analyst Todd Thomas upgraded EPR Properties (NYSE:EPR) from Sector Weight to Overweight and announced a $47 price target.

Portfolio Pulse from richadhand@benzinga.com

June 02, 2023 | 9:03 am

AVGO

Keybanc analyst John Vinh maintains an Overweight rating on Broadcom (NASDAQ:AVGO) and raises the price target from $820 to $940.

Portfolio Pulse from richadhand@benzinga.com

June 02, 2023 | 9:02 am

RGNX

Baird analyst Brian Skorney initiates coverage on Regenxbio (NASDAQ:RGNX) with an Outperform rating and announces a price target of $42.

Portfolio Pulse from richadhand@benzinga.com

June 02, 2023 | 8:49 am

ACNT

Stifel analyst Vincent Anderson initiates coverage on Ascent Industries (NASDAQ:ACNT) with a Buy rating and announces a price target of $20.

Portfolio Pulse from richadhand@benzinga.com

June 02, 2023 | 8:39 am

AMAM

Oppenheimer analyst Matthew Biegler initiates coverage on Ambrx Biopharma (NASDAQ:AMAM) with an Outperform rating and announces a price target of $30.

Portfolio Pulse from richadhand@benzinga.com

June 02, 2023 | 8:38 am

KWR

Stifel analyst Vincent Anderson initiates coverage on Quaker Houghton (NYSE:KWR) with a Buy rating and announces a price target of $250.

Portfolio Pulse from richadhand@benzinga.com

June 02, 2023 | 8:37 am

ABR

Wedbush analyst Jay McCanless initiates coverage on Arbor Realty Trust (NYSE:ABR) with an Outperform rating and announces a price target of $15.

Portfolio Pulse from richadhand@benzinga.com

June 02, 2023 | 8:36 am

ACRV

Oppenheimer analyst Matthew Biegler initiates coverage on Acrivon Therapeutics (NASDAQ:ACRV) with an Outperform rating and a price target of $25.

Portfolio Pulse from richadhand@benzinga.com

June 02, 2023 | 8:35 am

DG

Piper Sandler analyst Peter Keith downgrades Dollar General (NYSE:DG) from Overweight to Neutral and lowers the price target from $275 to $178.

Portfolio Pulse from richadhand@benzinga.com

June 02, 2023 | 8:30 am